AI assistant
Protara Therapeutics, Inc. — Director's Dealing 2025
Jun 4, 2025
34057_dirs_2025-06-04_e602ea4a-4653-4620-94cc-f85486026e23.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2025-06-02
Reporting Person: CONKLING WILLIAM (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-02 | Common Stock | A | 50000 | — | Acquired | 50000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-02 | Stock Option (Right to Buy) | $3.30 | A | 200000 | Acquired | 2035-06-01 | Common Stock (200000) | Direct |
Footnotes
F1: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one third installments on the first, second and third anniversaries of June 2, 2025.
F2: 25% of the shares vest on the one year anniversary of June 2, 2025 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.